XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Jun. 30, 2025
Jun. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (5,057,523) $ (324,355)
Adjustments to reconcile net loss to net cash flows used in operating activities:    
Amortization of debt discount to interest expense 243,353
Stock based compensation 125,127
Derivative expense 343,399
Change in fair value of derivative liabilities 2,133,599
Depreciation expense 12,571
Increase in note payable for acquisition of Phytanix Bio 583,878
Changes in: operating assets and liabilities:    
Inventories (57) (2)
Prepaid expenses (48,272)
VAT receivable (25,108)
Accounts payable 265,012 16,892
Accrued liabilities 256,758 61,032
Net cash used in operating activities (1,167,263) (246,433)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Cash received in acquisition of Phytanix Bio 943,180
Net cash provided by investing activities 943,180
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from notes payable 1,176,606
Deferred offering costs (259,950)
Proceeds from sale of common stock 395,474 200
Proceeds from exercise of warrants 3,949,730
Proceeds from related party loans 77,756 45,769
Net cash provided by financing activities 4,422,960 962,625
NET INCREASE IN CASH 4,198,877 716,192
Effect of exchange rate adjustments on cash (117,219) (4,190)
CASH, beginning of period 14,531 1,625
CASH, end of period 4,096,189 713,627
SUPPLEMENTAL SCHEDULE OF CASH FLOW INFORMATION:    
Interest paid
Income taxes paid
NON-CASH INVESTING AND FINANCING INFORMATION:    
Net assets acquired of Phytanix Bio, net of cash received $ 1,399,079